BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10843452)

  • 21. Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts.
    Brems-Eskildsen AS; Zieger K; Toldbod H; Holcomb C; Higuchi R; Mansilla F; Munksgaard PP; Borre M; Ørntoft TF; Dyrskjøt L
    BMC Cancer; 2010 Nov; 10():646. PubMed ID: 21106093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized trial of narrow-band versus white-light cystoscopy for restaging (second-look) transurethral resection of bladder tumors.
    Herr HW
    Eur Urol; 2015 Apr; 67(4):605-8. PubMed ID: 25041849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular followup of newly diagnosed bladder cancer using urine samples.
    Shigyo M; Sugano K; Tobisu K; Tsukamoto T; Sekiya T; Kakizoe T
    J Urol; 2001 Oct; 166(4):1280-5. PubMed ID: 11547058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon-a2b reduces neo-microvascular density in the 'normal' urothelium adjacent to the tumor after transurethral resection of superficial bladder carcinoma.
    Giannopoulos A; Adamakis I; Evangelou K; Giannopoulou M; Zacharatos P; Zsantoulis P; Perunovic B; Athanasiou A; Retalis G; Constandinidis C; Gorgoulis VG
    Onkologie; 2003 Apr; 26(2):147-52. PubMed ID: 12771523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
    Herr HW
    J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients.
    Serretta V; Lo Presti D; Vasile P; Gange E; Esposito E; Menozzi I
    Urology; 1998 Nov; 52(5):793-6. PubMed ID: 9801101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of the nuclear matrix protein 22 Bladder Chek test™ in the diagnosis of residual urothelial cancer before a second transurethral resection of bladder cancer.
    Balci M; Tuncel A; Guzel O; Aslan Y; Sezgin T; Bilgin O; Senel C; Atan A
    Int Urol Nephrol; 2015 Mar; 47(3):473-7. PubMed ID: 25649031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
    Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
    Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prognostic factors of superficial bladder cancer recurring after initial transurethral resection].
    Nakata S; Nakano K; Takahashi H; Shimizu K
    Hinyokika Kiyo; 2005 Apr; 51(4):229-33. PubMed ID: 15912780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conservative treatment of high grade superficial bladder tumours.
    Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
    Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical Benefits of Transurethral Resection Under Narrow Band Imaging for Non-Muscle Invasive Bladder Cancer].
    Mita K; Kobatake K; Ohara S; Kato M
    Hinyokika Kiyo; 2018 Jan; 64(1):1-6. PubMed ID: 29471596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The expression of thymidine phosphorylase is a prognostic predictor for the intravesical recurrence of superficial bladder cancer.
    Nonomura N; Nakai Y; Nakayama M; Inoue H; Nishimura K; Hatanaka E; Arima R; Kishimoto T; Miki T; Kuroda H; Okuyama A
    Int J Clin Oncol; 2006 Aug; 11(4):297-302. PubMed ID: 16937303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the Value of Combined Urine Cytology and Cystoscopy for Follow-up of Superficial Transitional Cell Carcinoma of the Urinary Bladder.
    Tahoun NS; Abdel Maksoud AM; Mohamed DB
    J Egypt Natl Canc Inst; 2010 Jun; 22(2):105-11. PubMed ID: 21860467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of screening methods in the detection of bladder cancer.
    Ramakumar S; Bhuiyan J; Besse JA; Roberts SG; Wollan PC; Blute ML; O'Kane DJ
    J Urol; 1999 Feb; 161(2):388-94. PubMed ID: 9915409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR.
    Orsola A; Cecchini L; Raventós CX; Trilla E; Planas J; Landolfi S; de Torres I; Morote J
    BJU Int; 2010 Jan; 105(2):202-7. PubMed ID: 19558557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin for prophylaxis of recurrence of superficial bladder cancer: a preliminary report.
    Uekado Y; Hirano A; Shinka T; Ohkawa T
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S65-8. PubMed ID: 7994790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Short-term versus long-term chemoprevention of recurrence with Epodyl following transurethral resection of superficial urinary bladder cancer].
    Flamm J; Kühnel W; Dona S
    Urologe A; 1989 Mar; 28(2):99-102. PubMed ID: 2655259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
    Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M
    Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.